Search alternatives:
mean decrease » a decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
nm decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), teer decrease (Expand Search)
Showing 621 - 640 results of 56,666 for search '(( 5 ((nn decrease) OR (mean decrease)) ) OR ( 5 ((nm decrease) OR (we decrease)) ))', query time: 0.91s Refine Results
  1. 621
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 622
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 623
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 624
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 625
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 626
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 627
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 628
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 629
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 630
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 631
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 632
    Type and duration of leisure-time activities performed 5 years after RYGB.

    Type and duration of leisure-time activities performed 5 years after RYGB. by Alice Bellicha (3583493)

    Published 2022
    Save to List
    Saved in:
  13. 633
    Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced respiratory burst.

    Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced respiratory burst. by Jian Hao (160736)

    Published 2013
    Save to List
    Saved in:
  14. 634
    AA-deficient <i>sfx</i> mice had decreased articular cartilage.

    AA-deficient <i>sfx</i> mice had decreased articular cartilage. by Richard C. Lindsey (7148168)

    Published 2019
    Save to List
    Saved in:
  15. 635
    Fig 3 Data.

    Fig 3 Data. by Kevin D. Gaitonde (15411707)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  16. 636
    S2 Fig Data.

    S2 Fig Data. by Kevin D. Gaitonde (15411707)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  17. 637
    Fig 2D–2F Data.

    Fig 2D–2F Data. by Kevin D. Gaitonde (15411707)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  18. 638
    Fig 6 Data.

    Fig 6 Data. by Kevin D. Gaitonde (15411707)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  19. 639
    Fig 1 Data.

    Fig 1 Data. by Kevin D. Gaitonde (15411707)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  20. 640
    Fig 2A–2C and 2G–2L Data.

    Fig 2A–2C and 2G–2L Data. by Kevin D. Gaitonde (15411707)

    Published 2023
    Subjects:
    Save to List
    Saved in:

Search Tools: